Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Therapeutic Targeting Of Cancer Stem Like Cells Csc The Current State Of The Art PDF full book. Access full book title Therapeutic Targeting Of Cancer Stem Like Cells Csc The Current State Of The Art.
| Author | : Cyril Corbet |
| Publisher | : Frontiers Media SA |
| Total Pages | : 192 |
| Release | : 2020-04-03 |
| Genre | : |
| ISBN | : 288963647X |
| Author | : Cyril Corbet |
| Publisher | : |
| Total Pages | : 0 |
| Release | : 2020 |
| Genre | : |
| ISBN | : |
This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact.
| Author | : Anne Le |
| Publisher | : Springer |
| Total Pages | : 186 |
| Release | : 2018-06-26 |
| Genre | : Medical |
| ISBN | : 331977736X |
Genetic alterations in cancer, in addition to being the fundamental drivers of tumorigenesis, can give rise to a variety of metabolic adaptations that allow cancer cells to survive and proliferate in diverse tumor microenvironments. This metabolic flexibility is different from normal cellular metabolic processes and leads to heterogeneity in cancer metabolism within the same cancer type or even within the same tumor. In this book, we delve into the complexity and diversity of cancer metabolism, and highlight how understanding the heterogeneity of cancer metabolism is fundamental to the development of effective metabolism-based therapeutic strategies. Deciphering how cancer cells utilize various nutrient resources will enable clinicians and researchers to pair specific chemotherapeutic agents with patients who are most likely to respond with positive outcomes, allowing for more cost-effective and personalized cancer therapeutic strategies.
| Author | : Khawaja Husnain Haider |
| Publisher | : Walter de Gruyter GmbH & Co KG |
| Total Pages | : 340 |
| Release | : 2018-12-17 |
| Genre | : Medical |
| ISBN | : 3110586916 |
This book is a compilation of the bench experience of leading experts from various research labs involved in the cutting edge area of research. The authors describe the use of stem cells both as part of the combinatorial therapeutic intervention approach and as tools (disease model) during drug development, highlighting the shift from a conventional symptomatic treatment strategy to addressing the root cause of the disease process. The book is a continuum of the previously published book entitled "Stem Cells: from Drug to Drug Discovery" which was published in 2017.
| Author | : Susie Nilsson |
| Publisher | : Academic Press |
| Total Pages | : 246 |
| Release | : 2021-02-09 |
| Genre | : Science |
| ISBN | : 0323853250 |
The Cancer Stem Cell Niche, Volume Five in the Advances in Stem Cells and their Niches series, highlights new advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including Acute lymphoblastic leukemia and the bone marrow microenvironment, Stem cell niches in bone and their roles in cancer metastasis, The role of vasculature in cancer stem cell niches, The lung cancer stem cell niche, The prostate cancer stem cell niche: Genetic drivers and therapeutic approaches, Impact of prostate cancer stem cell niches on prostate cancer tumorigenesis and progression, The testicular cancer stem cell niche. Provides the authority and expertise of leading contributors from an international board of authors Presents the latest release in the Advances in Stem Cells and their Niches series Includes the latest information on the Cancer Stem Cell Niche
| Author | : Varun Prabhu |
| Publisher | : |
| Total Pages | : |
| Release | : 2016 |
| Genre | : |
| ISBN | : |
Colorectal cancer (CRC) tumors contain a rare population of self-renewing stem cell-like cells (CRCSCs) that contribute to tumor maintenance and therapy resistance. Therapeutic targeting of CRCSCs could improve treatment response and prolong patient survival. The endogenous TNF-related apoptosis-inducing ligand (TRAIL) protein selectively induces cell death in cancer cells while sparing normal cells. Small molecule ONC201/TIC10 induces TRAIL-mediated cell death in cancer cells via transcription factor Foxo3a, which is activated by dual inhibition of Akt and ERK. ONC201/TIC10 is currently being tested in phase I/II clinical trials for patients with advanced cancer. This study investigates whether the potent anti-tumor effect of ONC201/TIC10 in CRC involves targeting CRCSCs. ONC201/TIC10 depletes CRCSC markers and prevents chemotherapy-resistant CRCSC-mediated self-renewal in colonosphere assays and xenograft tumor initiation studies in mice. ONC201/TIC10 significantly induces cell surface TRAIL in CRCSCs. ONC201/TIC10-mediated anti-CRCSC effect is significantly blocked by the TRAIL sequestering antibody RIK-2, overexpression of Akt and Foxo3a knockdown. The identification and demonstration of CRCSCs as a target of ONC201/TIC10 provides an innovative biomarker that could be monitored in the clinic. Tumor suppressor p53 is frequently mutated or inactivated in CRC. In contrast, p53 family member p73 is rarely mutated in CRC and p73 activation elicits p53-like tumor suppression. p53 restoration is known to target CRCSCs, but p73 restoration in CRCSCs has not been examined. This study investigates the effects of small molecule prodigiosin-mediated p73 activation on CRCSCs. Prodigiosin reduces chemotherapy-resistant CRCSC-mediated colonosphere formation and xenograft tumor initiation. Mechanistic studies reveal that prodigiosin increases the levels of p73 and reduces levels of the oncogenic N-terminally truncated isoform [delta]Np73 in CRCSCs. Accordingly, p73 knockdown or [delta]Np73 overexpression suppress prodigiosin-mediated CRCSC inhibition. Moreover, prodigiosin increases levels of the transcription factor c-Jun, a regulator of p73 and [delta]Np73. c-Jun knockdown attenuates prodigiosin-mediated [delta]Np73 downregulation, p73 activation and cell death. These findings have previously unrecognized implications for the use of p73 activating therapeutics and [delta]Np73 inhibition for targeting CRCSCs. Together, these results demonstrate that potent small molecules targeting CRCSCs via tumor suppressive pathways such as p73 and TRAIL are a viable potential approach for robust and durable cancer therapy.
| Author | : Cristina Maccalli |
| Publisher | : Springer |
| Total Pages | : 256 |
| Release | : 2020-08-14 |
| Genre | : Medical |
| ISBN | : 9783030166267 |
This book represents an up-dated summary of the state of the art of the characterization of cancer stem cell/ cancer initiating cell (CSC/CIC) properties. An overview of the definition and biological properties of CSCs/CICs as well as the role of these cells in determining the resistance to standard and immune-based therapies is provided. It also discusses limitations in the achievement of a definitive biological characterization of CSCs/CICs due to their high extent of plasticity and heterogeneity that is also mutually driven by the interaction of these cells with the tumor microenvironment. The limitations in targeting CSCs/CICs with immunotherapy are also explained together with explorative combination approaches that could increase the susceptibility of these cells to the recognition by immune cells. This book is conceived for a broad audience, including students, teachers, scientific experts. The critical revision of available results in terms of immunological profile of CSCs/CICs and the efficacy in targeting these cells by immunological approaches, results in a comprehensive and up to date recapitulation of the field and provides interesting suggestions on how to focus future investigations in order to assess the role of CSCs/CICs as prognostic and predictive biomarkers of responsiveness to therapies for cancer patients.
| Author | : David J. Kerr |
| Publisher | : Oxford University Press |
| Total Pages | : 2837 |
| Release | : 2016-01-28 |
| Genre | : Medical |
| ISBN | : 0191065110 |
Written and edited by internationally recognised leaders in the field, the new edition of the Oxford Textbook of Oncology has been fully revised and updated, taking into consideration the advancements in each of the major therapeutic areas, and representing the multidisciplinary management of cancer. Structured in six sections, the book provides an accessible scientific basis to the key topics of oncology, examining how cancer cells grow and function, as well as discussing the aetiology of cancer, and the general principles governing modern approaches to oncology treatment. The book examines the challenges presented by the treatment of cancer on a larger scale within population groups, and the importance of recognising and supporting the needs of individual patients, both during and after treatment. A series of disease-oriented, case-based chapters, ranging from acute leukaemia to colon cancer, highlight the various approaches available for managing the cancer patient, including the translational application of cancer science in order to personalise treatment. The advice imparted in these cases has relevance worldwide, and reflects a modern approach to cancer care. The Oxford Textbook of Oncology provides a comprehensive account of the multiple aspects of best practice in the discipline, making it an indispensable resource for oncologists of all grades and subspecialty interests.
| Author | : Tuula Kallunki |
| Publisher | : MDPI |
| Total Pages | : 302 |
| Release | : 2020-11-17 |
| Genre | : Science |
| ISBN | : 3039434403 |
Despite the efficiency of current cancer treatments, cancer is still a deadly disease for too many. In 2008, 7.6 million people died of cancer; with the current development, it is estimated that the annual cancer death number will grow to 13 million by 2030. There is clearly a need for not only more research but also more innovative and out of the mainstream scientific ideas to discover and develop even better cancer treatments. This book presents the collective works published in the recent Special Issue entitled “Killing Cancer: Discovery and Selection of New Target Molecules”. These articles comprise a selection of studies, ideas, and opinions that aim to facilitate knowledge, thoughts, and discussion about which biological and molecular mechanisms in cancer we should target and how we should target them.
| Author | : Guido Bocci |
| Publisher | : Springer |
| Total Pages | : 302 |
| Release | : 2014-09-04 |
| Genre | : Medical |
| ISBN | : 3662436043 |
This book analyzes all aspects of metronomic chemotherapy, a new approach involving low-dose, long-term, and frequently administered therapy that has preclinical and clinical activity in various tumors. After an opening section on the pharmacological bases of metronomic chemotherapy, including its antiangiogenic effects and impact on immunity, preclinical studies on various classes of drug are discussed. Clinical applications of metronomic chemotherapy in a wide variety of tumors are then addressed in detail, with description of the results of all published studies. The clinical pharmacology of metronomic chemotherapy is also considered in depth, encompassing pharmacokinetics, pharmacogenetics, pharmacoeconomics, and adverse drug reactions. The book closes by describing the role of this therapy in the veterinarian clinic.
